Sunday, October 31, 2010

Desquam-X Wash



benzoyl peroxide

Dosage Form: topical solution
WATER BASE

Desquam-X 5 Wash

(5% benzoyl peroxide)

WATER BASE

Desquam-X 10 Wash

(10% benzoyl peroxide)

Rx only

Desquam-X Wash Description


DESQUAM-X5 (5% benzoyl peroxide) and DESQUAM-X10 (10% benzoyl peroxide) brand topical therapeutic anti-acne cleansers contains benzoyl peroxide (5% and 10% respectively) in a lathering water base of sodium octoxynol- 3 sulfonate, dioctyl sodium sulfo-succinate, magnesium aluminum silicate, methylcellulose and EDTA.


Molecular structure




Desquam-X Wash - Clinical Pharmacology


The effectiveness of benzoyl peroxide in the treatment of acne vulgaris is primarily attributable to its antibacterial activity, especially with respect to Propionibacterium acnes, the predominant organism in sebaceous follicles and comedones.1,2 The antibacterial activity of this compound is presumably due to the release of active or free-radical oxygen capable of oxidizing bacterial proteins.3 In acne patients treated topically with benzoyl peroxide, resolution of the acne usually coincides with reduction in the levels of P. acnes and free fatty acids (FFA). Mild desquamation is another observed action of topically applied benzoyl peroxide and may also play a role in the drug’s effectiveness in acne.3 Studies also indicate that topical benzoyl peroxide may exert a se-bostatic effect with a resultant reduction of skin surface lipids.4,5


Benzoyl peroxide has been shown to be absorbed by the skin, where it is metabolized to benzoic acid and then excreted as benzoate in the urine.6



Indications and Usage for Desquam-X Wash


DESQUAM-X 5 and DESQUAM-X 10 Wash are indicated for the topical treatment of mild to moderate acne. In more severe cases, it may be used as an adjunct in therapeutic regimens including benzoyl peroxide gels, antibiotics, retinoic acid products and sulfur/salicylic acid-containing preparations. The improvement of the treated condition is dependent on the degree and type of acne, the frequency of use of Desquam-X Wash and the nature of other therapies employed.



Contraindications


This product should not be used in patients known to be sensitive to benzoyl peroxide or any other of the listed ingredients.



Precautions



General:


Avoid contact with eyes and other mucous membranes. For external use only. In patients known to be sensitive to the following substances, there is a possibility of cross-sensitization: benzoic acid derivatives (including certain topical anesthetics) and cinnamon.



Information for Patients:


This product may bleach colored fabric or hair. Concurent use with PABA-containing sunscreens may result in transient discoloration of the skin.



Carcinogenesis, Mutagenesis, Impairment of Fertility:


Based upon considerable evidence, benzoyl peroxide is not considered to be a carcinogen. However, in one study, using mice known to be highly susceptible to cancer, there was evidence for benzoyl peroxide as a tumor promoter. Benzoyl peroxide has been found to be inactive as a mutagen in the Ames Salmonella and other assays, including the mouse dominant lethal assay. This assay is frequently used to assess the effect of substances on spermatogenesis.



Pregnancy (Category C):


Animal reproduction studies have not been conducted with benzoyl peroxide (Desquam-X Wash). It is also not known whether benzoyl peroxide can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Benzoyl peroxide should be given to a pregnant woman only if clearly needed.



Nursing Mothers:


It is not known whether this drug is excreted in human milk. Caution should be exercised when benzoyl peroxide is administered to a nursing woman.



Pediatric Use:


Safety and effectiveness in children below the age of 12 have not been established.



Adverse Reactions


Adverse reactions which may be encountered with topical benzoyl peroxide include excessive drying (manifested by marked peeling, erythema and possible edema), and allergic contact sensitization.


Excessive dryness would appear to occur in approximately 2 patients in 50.


Pertinent literature would seem to indicate that allergic sensitization to benzoyl peroxide may occur in 10 to 25 patients in 1,000.7,8,9 There is one reference that reports an occurrence of sensitization in 5 of 100 patients.10



Overdosage


In the event that excessive scaling, erythema or edema occur, the use of this preparation should be discontinued. If the reaction is judged to be due to excessive use and not allergenicity, after symptoms and signs subside, a reduced dosage schedule may be cautiously tried.


To hasten resolution of the adverse effects, emollients, cool compresses and/or topical corticosteroid preparations may be used.



Desquam-X Wash Dosage and Administration


Shake well before use. Wash affected areas once or twice daily, avoiding contact with eyes or mucous membranes. Wet skin areas to be treated prior to administration; apply Desquam-X Wash, work to a full lather, rinse thoroughly and pat dry. The amount of drying or peeling may be controlled by modification of dose frequency or drug concentration.



How is Desquam-X Wash Supplied


Desquam-X Wash (5%): 5 oz. plastic bottle, NDC 10631-284-05.


Desquam-X Wash (10%): 5 oz. plastic bottle, NDC 10631-285-05.


Store at controlled room temperature (59°-86°F; 15°-30°C).



REFERENCES


  1. Kligman AM, Leyden JJ, Stewart R: New uses for benzoyl peroxide: A broad-spectrum antimicrobial agent. Int J Derm 16:413-417, 1977.

  2. Leyden JJ, Stewart R, Kligman AM: Updated invivo methods for evaluating topical antimicrobial agents on human skin. J Invest Dermatol 72:165-170, 1979.

  3. Fulton JE, Farzad-Bakshandeh A, Bradley S: Studies on the mechanism of action of topical benzoyl peroxide and vitamin-A acid in acne vulgaris. J Cut Path 1:191-200, 1974.

  4. Fanta D, Jurecka W: Autora-diographic investigation on benzoyl peroxide treated skin. ActaDermatovener 58:361-362, 1978.

  5. Fanta D, Muller MM: Effect of benzoyl peroxide on skin surface lipids. Dermatologica 158:55-59, 1979.

  6. Nacht S, Yeung D, Beasley J, Anjo M, Maibach HI: Benzoyl peroxide invitro and invivo skin penetration and metabolic disposition. Presented to Soc for Invest Derm, June 9-14, 1979. Amsterdam.

  7. Eaglstein WH: Allergic contact dermatitis to benzoyl peroxide. Arch Dermatol 97:527, 1968.

  8. Pace WE: A benzoyl peroxide-sulfur cream for acne vulgaris. Canad Med Assoc J 93:252-253, 1965.

  9. Vasarinsh P: Benzoyl peroxide-sulfur lotions in acne vulgaris — a controlled study. Cutis 5(1):65-69, 1969.

  10. Fanta D: Clinical and experimental studies with benzoyl peroxide in the treatment of acne. Hautzart 29:481- 486, 1978.

RANBAXY


Jacksonville, FL 32257 USA


Revised June 2008



PACKAGE LABEL. PRINCIPAL DISPLAY PANEL



Desquam-X Wash (5%)


140 gram bottle (front)



140 gram bottle (back)




Desquam-X Wash (10%)


140 gram bottle (front)



140 gram bottle (back)










DESQUAM-X  WASH
benzoyl peroxide  solution










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)10631-284
Route of AdministrationTOPICALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
BENZOYL PEROXIDE (BENZOYL PEROXIDE)BENZOYL PEROXIDE5 mg  in 1 mL








Inactive Ingredients
Ingredient NameStrength
EDETIC ACID 
MAGNESIUM ACETATE 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
110631-284-05148 mL In 1 BOTTLE, PLASTICNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved drug other08/27/2008







DESQUAM-X  WASH
benzoyl peroxide  solution










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)10631-285
Route of AdministrationTOPICALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
BENZOYL PEROXIDE (BENZOYL PEROXIDE)BENZOYL PEROXIDE10 mg  in 1 mL








Inactive Ingredients
Ingredient NameStrength
EDETIC ACID 
MAGNESIUM ACETATE 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
110631-285-05148 mL In 1 BOTTLE, PLASTICNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved drug other05/02/2008


Labeler - Ranbaxy Laboratories Inc. (169932519)

Registrant - Ranbaxy Laboratories Inc. (169932519)









Establishment
NameAddressID/FEIOperations
Contract Pharmaceuticals Limited248761249manufacture
Revised: 11/2009Ranbaxy Laboratories Inc.

More Desquam-X Wash resources


  • Desquam-X Wash Side Effects (in more detail)
  • Desquam-X Wash Use in Pregnancy & Breastfeeding
  • Desquam-X Wash Drug Interactions
  • Desquam-X Wash Support Group
  • 1 Review for Desquam-X - Add your own review/rating


  • Desquam-X Wash Concise Consumer Information (Cerner Multum)

  • Acne Treatment Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • BenzEFoam Foam MedFacts Consumer Leaflet (Wolters Kluwer)

  • Benzac Topical Advanced Consumer (Micromedex) - Includes Dosage Information

  • Benzac AC Wash MedFacts Consumer Leaflet (Wolters Kluwer)

  • Brevoxyl Gel MedFacts Consumer Leaflet (Wolters Kluwer)

  • Brevoxyl Creamy Wash Concise Consumer Information (Cerner Multum)

  • Inova Pads MedFacts Consumer Leaflet (Wolters Kluwer)

  • NeoBenz Micro Wash Plus Pack Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • Oxy Balance Topical Advanced Consumer (Micromedex) - Includes Dosage Information

  • PanOxyl Bar MedFacts Consumer Leaflet (Wolters Kluwer)

  • Triaz Cloths MedFacts Consumer Leaflet (Wolters Kluwer)

  • Triazolam Monograph (AHFS DI)



Compare Desquam-X Wash with other medications


  • Acne
  • Perioral Dermatitis

Sunday, October 24, 2010

Atenololo DOC




Atenololo DOC may be available in the countries listed below.


Ingredient matches for Atenololo DOC



Atenolol

Atenolol is reported as an ingredient of Atenololo DOC in the following countries:


  • Italy

International Drug Name Search

Saturday, October 23, 2010

Proxigen




Proxigen may be available in the countries listed below.


Ingredient matches for Proxigen



Piroxicam

Piroxicam is reported as an ingredient of Proxigen in the following countries:


  • Colombia

International Drug Name Search

Aminalonum




Aminalonum may be available in the countries listed below.


Ingredient matches for Aminalonum



Aminobutyric Acid, þ-

Aminobutyric Acid, þ- is reported as an ingredient of Aminalonum in the following countries:


  • Latvia

International Drug Name Search

Thursday, October 21, 2010

Caluniatin




Caluniatin may be available in the countries listed below.


Ingredient matches for Caluniatin



Kallidinogenase

Kallidinogenase is reported as an ingredient of Caluniatin in the following countries:


  • Japan

International Drug Name Search

Soluciones Parenterales




Soluciones Parenterales may be available in the countries listed below.


Ingredient matches for Soluciones Parenterales



Potassium Chloride

Potassium Chloride is reported as an ingredient of Soluciones Parenterales in the following countries:


  • Argentina

Sodium Bicarbonate

Sodium Bicarbonate is reported as an ingredient of Soluciones Parenterales in the following countries:


  • Argentina

International Drug Name Search

Monday, October 18, 2010

Clozapine-Hexal




Clozapine-Hexal may be available in the countries listed below.


Ingredient matches for Clozapine-Hexal



Clozapine

Clozapine is reported as an ingredient of Clozapine-Hexal in the following countries:


  • Poland

  • South Africa

International Drug Name Search

Sunday, October 17, 2010

Enalapril Perugen




Enalapril Perugen may be available in the countries listed below.


Ingredient matches for Enalapril Perugen



Enalapril

Enalapril is reported as an ingredient of Enalapril Perugen in the following countries:


  • Peru

International Drug Name Search

Monday, October 11, 2010

Paracetamol Alpharma ApS




Paracetamol Alpharma ApS may be available in the countries listed below.


Ingredient matches for Paracetamol Alpharma ApS



Paracetamol

Paracetamol is reported as an ingredient of Paracetamol Alpharma ApS in the following countries:


  • Singapore

International Drug Name Search

Monday, October 4, 2010

Lansoprazol Lareq




Lansoprazol Lareq may be available in the countries listed below.


Ingredient matches for Lansoprazol Lareq



Lansoprazole

Lansoprazole is reported as an ingredient of Lansoprazol Lareq in the following countries:


  • Spain

International Drug Name Search

Apo-Meloxicam




Apo-Meloxicam may be available in the countries listed below.


Ingredient matches for Apo-Meloxicam



Meloxicam

Meloxicam is reported as an ingredient of Apo-Meloxicam in the following countries:


  • Canada

International Drug Name Search

Saturday, October 2, 2010

Biperin




Biperin may be available in the countries listed below.


Ingredient matches for Biperin



Biperiden

Biperiden hydrochloride (a derivative of Biperiden) is reported as an ingredient of Biperin in the following countries:


  • Taiwan

International Drug Name Search

Friday, October 1, 2010

Omeprazolo ratiopharm




Omeprazolo ratiopharm may be available in the countries listed below.


Ingredient matches for Omeprazolo ratiopharm



Omeprazole

Omeprazole is reported as an ingredient of Omeprazolo ratiopharm in the following countries:


  • Italy

International Drug Name Search